PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β

The development of targeted tyrosine kinase inhibitors (TKIs) has succeeded in altering the course of chronic myeloid leukemia (CML). However, a number of patients have failed to respond or experienced disease relapse following TKI treatment. Proviral integration site for moloney murine leukemia vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Rui-Fang, Lu, Ying, Fang, Zhi-Gang, Guo, Xiao-Yan, Chen, Yu-Xin, Xu, Yi-Chuan, Lei, Ya-Mei, Liu, Ke-Fang, Lin, Dong-Jun, Liu, Ling-Ling, Liu, Xiang-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647015/
https://www.ncbi.nlm.nih.gov/pubmed/28849186
http://dx.doi.org/10.3892/mmr.2017.7215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647015/
https://www.ncbi.nlm.nih.gov/pubmed/28849186
http://dx.doi.org/10.3892/mmr.2017.7215

Ejemplares similares